These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10561203)

  • 1. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
    Bernhard J; Thürlimann B; Schmitz SF; Castiglione-Gertsch M; Cavalli F; Morant R; Fey MF; Bonnefoi H; Goldhirsch A; Hürny C
    J Clin Oncol; 1999 Jun; 17(6):1672-9. PubMed ID: 10561203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).
    Bernhard J; Castiglione-Gertsch M; Schmitz SF; Thürlimann B; Cavalli F; Morant R; Fey MF; Bonnefoi H; Goldhirsch A; Hürny C
    Eur J Cancer; 1999 Jun; 35(6):913-20. PubMed ID: 10533471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
    Goss PE; Winer EP; Tannock IF; Schwartz LH
    J Clin Oncol; 1999 Jan; 17(1):52-63. PubMed ID: 10458218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
    Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
    Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical trial of lentaron for postmenopausal patients with advanced breast cancer].
    Liu X; Song S; Jiang Z; Wu S; Yu J; Wang T
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):511-3. PubMed ID: 12485513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
    Wiseman LR; Goa KL
    Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
    Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Zilembo N; Dugardyn JL; Nasurdi C; Mennel RG; Cervek J; Fowst C; Polli A; di Salle E; Arkhipov A; Piscitelli G; Miller LL; Massimini G
    J Clin Oncol; 2000 Apr; 18(7):1399-411. PubMed ID: 10735887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
    Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
    Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
    J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
    Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
    Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
    J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.
    Muss HB; Wells HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Powell BL
    J Clin Oncol; 1988 Jul; 6(7):1098-106. PubMed ID: 3292710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group.
    Coates AS; Hürny C; Peterson HF; Bernhard J; Castiglione-Gertsch M; Gelber RD; Goldhirsch A
    J Clin Oncol; 2000 Nov; 18(22):3768-74. PubMed ID: 11078489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.
    Jones S; Vogel C; Arkhipov A; Fehrenbacher L; Eisenberg P; Cooper B; Honig S; Polli A; Whaley F; di Salle E; Tiffany J; Consonni A; Miller L
    J Clin Oncol; 1999 Nov; 17(11):3418-25. PubMed ID: 10550136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Megestrol acetate therapy for advanced breast cancer.
    Gregory EJ; Cohen SC; Oines DW; Mims CH
    J Clin Oncol; 1985 Feb; 3(2):155-60. PubMed ID: 3838187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
    Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
    Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer.
    Paterson AH; Hanson J; Pritchard KI; Sansregret E; Dahrouge S; McDermot RS; Fine S; White DF; Trudeau M; Stewart DJ
    Semin Oncol; 1990 Dec; 17(6 Suppl 9):52-62. PubMed ID: 2259927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe immune thrombocytopenia during formestane treatment.
    Español I; Muñíz-Díaz E; Alonso MC; Pujol-Moix N
    Haematologica; 1998 Oct; 83(10):953-4. PubMed ID: 9830809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
    Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E
    Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.